June 23

Turned away from five clinical trials, a cancer patient waits for one that will take him

first_img Senior Writer, Biotech Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast. Turned away from five clinical trials, a cancer patient waits for one that will take him Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. @adamfeuerstein About the Authors Reprints Damian Garde What is it? GET STARTED By Rebecca Robbins, Damian Garde , and Adam Feuerstein Feb. 28, 2020 Reprints @damiangarde Biotech center_img Todd Mercer in a 2017 photo with his wife, Amanda; daughter, Dawsen, now 15; and son, Dex, now 13. Courtesy Todd Mercer Log In | Learn More [email protected] Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. First 30 days free. GET STARTED What’s included? Adam Feuerstein National Biotech Reporter Damian covers biotech, is a co-writer of The Readout newsletter, and a co-host of “The Readout LOUD” podcast. [email protected] It’s hard enough for any cancer patient to get into clinical trials. It’s even harder for a patient with a rare cancer like Todd Mercer.Mercer, a 52-year-old defense industry professional, lives in Michigan with his wife and their two teenagers. At age 50, Mercer got a colonoscopy, as is recommended for people his age, and received a clean bill of health. Six weeks later, his appendix burst. Tags cancerdrug developmentresearchlast_img read more